Objective To study the clinical effects of Icotinib Hydrochloride in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A retrospective analysis of 63 patients with stage ⅢB to stage Ⅳadvanced NSCLC who were treated with icotinib hydrochloride in Beijing Huairou Hospital from January 2014 to July 2017. All patients received only icotinib hydrochloride treatment. A total of 63 cases were observed The patient′s clinical characteristics,treatment effects, adverse reactions and survival time. Analyze the relevant influencing factors of the recent efficacy.According to whether the pathological type is adenocarcinoma, a total of 63 patients were divided into adenocarcinoma group (51 cases) and non-adenocarcinoma group (12 cases), and the disease control rate (DCR) and survival curve of the two groups were compared. Results Among the 63 patients, a total of 12 had partial remission (PR), a total of 30 had stable disease (SD), and 21 had disease progression (PD). The objective response rate (ORR) was 19.0%, and the DCR was 66.7%. The time to disease progression (MPFS) was (7.41±3.75) months. The main adverse reactions were rash in 23 cases (36.5%) and diarrhea in 14 cases (22.2%). The occurrence of rash and diarrhea was mainly grade Ⅰand grade Ⅱ, can be relieved after symptomatic treatment. Univariate analysis revealed that the pathological type was the influencing factor of DCR (P＜0.05). The 6-month DCR of the adenocarcinoma group was higher than that of the non-adenocarcinoma group, and the difference was statistically significant (P＜0.05). The survival ccurve of the adenocarcinoma group was better than that of the non-adenocarcinoma group, and the difference was statistically significant(P＜0.05). Conclusion Icotinib Hydrochloride is certainly effective for late NSCLC, especially in patients with adenocarcinoma, and the adverse effects are mild after application, which is worthy of use.